A faster, more accurate test for HIT antibodies
Official title: An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia
Funded at Retham Technologies, INC. · NIH-11314485 · Data updated 2026-11-12
A new in vitro diagnostic test aims to quickly and accurately detect harmful antibodies linked to heparin-induced thrombocytopenia in patients who need help deciding on treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Retham Technologies, INC. NIH-funded |
| Lab location | 1 site (Wauwatosa, UNITED STATES) |
| Project start | June 15, 2019 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,693,897 |
| NIH project number | 5R44HL147734-05 |
| Project ID | NIH-11314485 on NIH RePORTER |
Who could benefit from this research
✓Could help
Hospitalized patients suspected of HIT who require timely and accurate diagnostic results to guide anticoagulant therapy.
✕Less likely to help
Patients without suspected HIT or those who already have a confirmed alternative diagnosis may not benefit.
What this research studies
This project develops an IVD test that uses PF4-treated platelets to identify clinically important HIT antibodies. It focuses on validating both the analytical performance and the real-world clinical usefulness of the assay so labs can diagnose HIT more reliably. By replacing or speeding up current tests, doctors could make safer treatment choices for patients on heparin. The work is designed to move from Phase IIB toward broader clinical adoption in hospital settings.
Why it matters
Potential benefit: If successful, the test could shorten diagnosis time and reduce inappropriate exposure to risky anticoagulants for patients with suspected HIT.
How similar studies have gone: Previous HIT diagnostic approaches have limitations; this project aims to improve accuracy and turnaround time with a functional assay.
Where this research is happening
-
Retham Technologies, INC.
Wauwatosa, United States Active
Researchers
- Principal investigator: Jones, Curtis — Retham Technologies, INC.
- Study coordinator: Jones, Curtis
Related research
Other NIH-funded projects on the same topics.
-
Developing a test to detect harmful antibodies related to Heparin-induced Thrombocytopenia
This study is working on a new, more accurate test to help doctors find out if patients have Heparin-induced Thrombocytopenia (HIT), a serious condition that can happen when they receive heparin treatment, so that patients can get the right care without the confusion of false-positive results from current tests.
-
A New Test for Heparin-Induced Thrombocytopenia (HIT)
This project is developing a more accurate and faster blood test to identify patients who have a serious reaction to heparin, called Heparin-induced Thrombocytopenia (HIT).
-
Developing a test to detect harmful antibodies related to Heparin-induced Thrombocytopenia
This study is working on a new, more accurate test to help doctors find out if patients have Heparin-induced Thrombocytopenia (HIT), a serious condition that can happen when they receive heparin treatment, so that patients can get the right care and feel better faster.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.